| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_1a4f52100fea36883c57d0fa1308b1f7
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_7e543a34638471d3d466cbb2cc14aaa9
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_7ae739b067fda3a4d47f77aa1dc7f66c |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-553
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-198
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-22
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D413-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-24
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D413-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-198
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-553 |
| filingDate |
2008-11-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_73faeb7413e11f3838fdf5653bcc94a7
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c871c31eb65132986858a86bcab1a320 |
| publicationDate |
2009-06-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2009069828-A1 |
| titleOfInvention |
Agent for improving motor complications or psychiatric symptoms in parkinson's disease |
| abstract |
It is intended to provide an agent for improving motor complications accompanying levodopa treatment of Parkinson's disease, delaying the onset of motor complications accompanying levodopa treatment, and inhibiting or delaying the progression of symptoms of Parkinson's disease, comprising a compound represented by the formula (I): a pharmacologically acceptable salt thereof or a hydrate thereof. The compound of the formula (I) has serotonin 1A receptor partial agonistic activity and also has a dopamine D3 receptor agonistic activity without having a dopamine D2 receptor antagonistic activity, has an effect of improving and delaying the onset of motor complications accompanying the repetitive administration of levodopa, and is effective also in accompanying psychiatric symptoms in patients with advanced-stage Parkinson's disease. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9668995-B2 |
| priorityDate |
2007-11-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |